Your browser doesn't support javascript.
Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists.
Mileham, Kathryn F; Schenkel, Caroline; Bruinooge, Suanna S; Freeman-Daily, Janet; Basu Roy, Upal; Moore, Amy; Smith, Robert A; Garrett-Mayer, Elizabeth; Rosenthal, Lauren; Garon, Edward B; Johnson, Bruce E; Osarogiagbon, Raymond U; Jalal, Shadia; Virani, Shamsuddin; Weber Redman, Mary; Silvestri, Gerard A.
  • Mileham KF; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.
  • Schenkel C; American Society of Clinical Oncology, Alexandria, Virginia, USA.
  • Bruinooge SS; American Society of Clinical Oncology, Alexandria, Virginia, USA.
  • Freeman-Daily J; The ROS1ders, Mountain View, California, USA.
  • Basu Roy U; LUNGevity Foundation, Chicago, Illinois, USA.
  • Moore A; LUNGevity Foundation, Chicago, Illinois, USA.
  • Smith RA; American Cancer Society National Lung Cancer Roundtable, Atlanta, Georgia, USA.
  • Garrett-Mayer E; American Society of Clinical Oncology, Alexandria, Virginia, USA.
  • Rosenthal L; American Cancer Society National Lung Cancer Roundtable, Atlanta, Georgia, USA.
  • Garon EB; University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA.
  • Johnson BE; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Osarogiagbon RU; Baptist Cancer Center, Memphis, Tennessee, USA.
  • Jalal S; Indiana University, Indianapolis, Indiana, USA.
  • Virani S; Aurora Health Care, Burlington, Wisconsin, USA.
  • Weber Redman M; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Silvestri GA; American Cancer Society National Lung Cancer Roundtable, Atlanta, Georgia, USA.
Cancer Med ; 11(2): 530-538, 2022 01.
Article in English | MEDLINE | ID: covidwho-1606588
ABSTRACT

BACKGROUND:

An ASCO taskforce comprised of representatives of oncology clinicians, the American Cancer Society National Lung Cancer Roundtable (NLCRT), LUNGevity, the GO2 Foundation for Lung Cancer, and the ROS1ders sought to characterize U.S. oncologists' biomarker ordering and treatment practices for advanced non-small-cell lung cancer (NSCLC); ascertain barriers to biomarker testing; and understand the impact of delays on treatment decisions.

METHODS:

We deployed a survey to 2374 ASCO members, targeting U.S. thoracic and general oncologists.

RESULTS:

We analyzed 170 eligible responses. For non-squamous NSCLC, 97% of respondents reported ordering tests for EGFR, ALK, ROS1, and BRAF. Testing for MET, RET, and NTRK was reported to be higher among academic versus community providers and higher among thoracic oncologists than generalists. Most respondents considered 1 (46%) or 2 weeks (52%) an acceptable turnaround time, yet 37% usually waited three or more weeks to receive results. Respondents who waited ≥3 weeks were more likely to defer treatment until results were reviewed (63%). Community and generalist respondents who waited ≥3 weeks were more likely to initiate non-targeted treatment while awaiting results. Respondents <5 years out of training were more likely to cite their concerns about waiting for results as a reason for not ordering biomarker testing (42%, vs. 19% with ≥6 years of experience).

CONCLUSIONS:

Respondents reported high biomarker testing rates in patients with NSCLC. Treatment decisions were impacted by test turnaround time and associated with practice setting and physician specialization and experience.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Biomarkers, Tumor / Carcinoma, Non-Small-Cell Lung / Clinical Decision-Making / Oncologists / Lung Neoplasms Type of study: Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: North America Language: English Journal: Cancer Med Year: 2022 Document Type: Article Affiliation country: Cam4.4459

Full text: Available Collection: International databases Database: MEDLINE Main subject: Biomarkers, Tumor / Carcinoma, Non-Small-Cell Lung / Clinical Decision-Making / Oncologists / Lung Neoplasms Type of study: Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: North America Language: English Journal: Cancer Med Year: 2022 Document Type: Article Affiliation country: Cam4.4459